Tango Therapeutics (TNGX) Other financing activities (2020 - 2026)
Tango Therapeutics (TNGX) posted quarterly Other financing activities of $17.6 million for Q1 2026, up 880150.0% year-over-year from N/an in Q1 2025, and up 880150.0% quarter-over-quarter from $2000.0 in Q1 2025.
Tango Therapeutics (TNGX) Other financing activities (2020 - 2026) Analysis & Trends
Tango Therapeutics' Other financing activities history runs 6 years deep, the most recent figure standing at $17.6 million for Q1 2026.
- In Q1 2026, Other financing activities rose 880150.0% year-over-year to $17.6 million; the TTM figure through Mar 2026 stood at $17.9 million (up 3969.16% YoY), while the FY2023 annual figure was $689000.0, changed N/A from the prior year.
- Other financing activities for Q1 2026 stood at $17.6 million, up from $2000.0 in the prior quarter.
- The five-year high for Other financing activities was $17.6 million in Q1 2026, with the low at $2000.0 in Q1 2025.
- The 4-year median for Other financing activities is $169000.0 (2022), against an average of $4.5 million.
- The sharpest annual moves came in 2023 and 2026: Other financing activities tumbled 72.45% in 2023, then jumped 880150.0% in 2026.
- Tango Therapeutics' Other financing activities stood at $265000.0 in 2022, then plunged by 72.45% to $73000.0 in 2023, then plunged by 97.26% to $2000.0 in 2025, then surged by 880150.0% to $17.6 million in 2026.
- Business Quant data shows TNGX's Other financing activities at $17.6 million in Q1 2026, $2000.0 in Q1 2025, and $73000.0 in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Tango Therapeutics | 4.32 Bn | 3.30 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 20.62 Mn |
| Jun 30, 2026 | 20.62 Mn |
| Mar 31, 2026 | 17.61 Mn |
| Mar 31, 2026 | 17.61 Mn |
| Mar 31, 2025 | 2,000.00 |
| Mar 31, 2025 | 2,000.00 |
| Mar 31, 2023 | 73,000.00 |
| Mar 31, 2023 | 73,000.00 |
| Mar 31, 2022 | 265,000.00 |
| Mar 31, 2022 | 265,000.00 |
| Dec 31, 2021 | 101,000.00 |
| Dec 31, 2021 | 101,000.00 |
| Mar 31, 2021 | 439,000.00 |
| Mar 31, 2021 | 439,000.00 |
| Dec 31, 2020 | 5.34 Mn |
| Dec 31, 2020 | 5.34 Mn |
| Sep 30, 2020 | 5.34 Mn |
| Sep 30, 2020 | 5.34 Mn |